Table 3.

Multivariate analyses of the association between recipient and donors with YKL-40 plasma concentrations at or above versus below the age adjusted 95% percentile.

		YKL-40 plasma concentration above the age adjusted 95% percentile
		Recipient			Donor
		N	HR (95% CI)	P	N	HR (95% CI)	P
Overall survivala		745	1.13 (0.89–1.43)	0.320	565	1.30 (0.95–1.79)	0.099
Disease free survivalb		745	1.07 (0.85–1.35)	0.573	565	1.13 (0.83–1.53)	0.441
Relapsec		745	1.13 (0.83–1.54)	0.436	565	1.25 (0.84–1.86)	0.277
Treatment related mortalityd		745	0.98 (0.69–1.38)	0.894	565	1.20 (0.75–1.94)	0.447
Acute GVHD
	Grade II–IVe	745	1.09 (0.84–1.41)	0.531	565	1.39 (1.00–1.94)	0.050
	Grade III–IVe	745	0.87 (0.55–1.37)	0.551	565	1.09 (0.62–1.93)	0.760

Patients who had the donor plasma YKL-40 concentration missing (n=205) were deemed ineligible for testing the donor plasma YKL-40 effect. In addition, 36 (or 11) patients were excluded in multivariate testing for recipient (or donor) plasma because of missing information on either the time-to-event endpoints or covariates that were adjusted in the models.

HR, hazard ratio; CI, confidence interval

^a: adjusted for patient age, patient BMI, disease status, HLA match, sex match, and conditioning regimen intensity.

^b: adjusted for patient age, patient BMI, cytogenetics, disease status, sex match, and conditioning regimen intensity.

^c: adjusted for patient age, cytogenetics, disease status, and conditioning regimen intensity.

^d: adjusted for patient BMI, disease, CMV match status, HLA match and conditioning regimen intensity.

^e: adjusted for disease, CMV match status, conditioning regimen and HLA match